natgillin/translations-raw huggingface dataset:
Patients should have their weight monitored regularly (see section 4.8). 
Pri bolnikih je treba redno spremljati telesno maso (glejte poglavje 4.8).
After discontinuation of cariprazine treatment contraception should be used for at least 10 weeks due to the slow elimination of active moieties. 
Po prekinitvi zdravljenja s kariprazinom je treba kontracepcijo uporabljati še vsaj 10 tednov zaradi počasnega izločanja aktivnih sestavin.
Do not breast-feed if you are taking Reagila because a risk for the baby cannot be excluded. 
Med jemanjem zdravila Reagila ne smete dojiti, saj tveganja za dojenčka ni možno izključiti.
Ask your doctor about appropriate choices of contraception. 
O ustrezni izbiri kontracepcije se posvetujte z zdravnikom.
No significant relationship was found between cariprazine plasma clearance and creatinine clearance. 
Pomembnega razmerja med plazemskim očistkom kariprazina in očistkom kreatinina niso ugotovili.
No QT interval prolongation was detected following supratherapeutic doses (9 mg/day or 18 mg/day). 
Podaljšanja intervala QT po supraterapevtskih odmerkih (9 mg/dan ali 18 mg/dan) niso opazili.
The effects of cariprazine on the QT interval were evaluated in patients with schizophrenia or schizoaffective disorder. 
Učinke kariprazina na interval QT so ocenili pri bolnikih s shizofrenijo ali shizoafektivno motnjo.
In case of severe extrapyramidal symptoms, anticholinergic medicinal products should be administered. 
V primeru resnih ekstrapiramidnih simptomov je treba dati antiholinergična zdravila.
In the population PK analysis there were no clinically relevant differences in the PK parameters (AUC and Cmax of the sum of cariprazine and its major active metabolites) based on age, gender and race. 
V analizi populacijske farmakokinetike ni bilo klinično pomembnih razlik v farmakokinetičnih parametrih (AUC in Cmax vsote kariprazina in njegovih glavnih aktivnih presnovkov) na podlagi starosti, spola in etnične pripadnosti.
However, a causal relationship between lenticular changes / cataracts observed in human studies and cariprazine use has not been established. 
Vendar pa vzročne povezanosti med spremembami leče/katarakto, ki so jo opazili v študijah pri ljudeh, in uporabo kariprazina niso dokazali.
As cariprazine causes akathisia and restlessness, it should be used cautiously in patients who are prone to or already exhibit symptoms of akathisia. 
Ker kariprazin povzroči akatizijo in nemir, ga je treba pri bolnikih, ki so nagnjeni k simptomom akatizije ali jih že kažejo, uporabljati previdno.
There are no or limited amount of data from the use of cariprazine in pregnant women. 
Podatkov o uporabi kariprazina pri nosečnicah ni oziroma so omejeni.
What Reagila is and what it is used for What you need to know before you take Reagila How to take Reagila 
Kaj je zdravilo Reagila in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Reagila Kako jemati zdravilo Reagila Možni neželeni učinki
Therefore CYP2D6 inhibitors are unlikely to have a clinically relevant effect on cariprazine metabolism. 
Zato ni verjetno, da bi zaviralci CYP2D6 imeli klinično pomemben učinek na presnovo kariprazina.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Možen vpliv drugih zdravil na kariprazin
What you need to know before you take Reagila 
Kaj morate vedeti, preden boste vzeli zdravilo Reagila
These are medicines used to treat heart diseases containing digoxin, blood thinners containing dabigatran, or medicines affecting your mental functions. 
Med temi so zdravila, ki se uporabljajo za zdravljenje bolezni srca in vsebujejo digoksin, sredstvo za redčenje krvi, ki vsebuje dabigatran, ali zdravila, ki vplivajo na duševne sposobnosti.
- ever experienced or start to experience abnormal, involuntary movements, most commonly of the tongue or face. 
- ste kadar koli imeli ali začenjate opažati nenormalne, nehotne gibe, najpogosteje jezika ali obraza.
Cariprazine has low affinity for serotonin 5-HT2C and adrenergic α1 receptors (Ki values of 134 nM and 155 nM, respectively). 
Kariprazin ima nizko afiniteto za serotoninske receptorje 5HT2C in adrenergične receptorje α1 (vrednosti Ki 134 nM in 155 nM).
In the long term maintenance of effect study, there was no clinically relevant difference in change of body weight from baseline to end of treatment (1.1 kg for cariprazine and 0.9 kg for placebo). 
V dolgoročni študiji vzdrževanja učinkovitosti ni bilo klinično pomembnih razlik v spremembi telesne mase od izhodišča do konca zdravljenja (1,1 kg za kariprazin in 0,9 kg za placebo).
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake »Uporabno« do in »EXP«.
Cariprazine has two pharmacologically active metabolites with similar activites as cariprazine, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR). 
Kariprazin ima dva farmakološko aktivna presnovka s podobno aktivnostjo kot kariprazin, desmetil kariprazin (DCAR) in didesmetil kariprazin (DDCAR).
Because of the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks. 
Zaradi dolge razpolovne dobe kariprazina in njegovih aktivnih presnovkov spremembe odmerka na koncentracijah v plazmi ne bodo v celoti vidne še nekaj tednov.
A 2-part study (a single dose of 1 mg cariprazine [Part A] and a daily dose of 0.5 mg cariprazine for 14 days [Part B] was conducted in patients with varying degrees of impaired hepatic function (ChildPugh Classes A and B). 
2-delno študijo (enkratni odmerek 1 mg kariprazina [del A] in dnevni odmerek 0,5 mg kariprazina v obdobju 14 dni [del B]) so izvedli pri bolnikih z različnimi stopnjami okvare jeter (razred A in B po Child-Pughu).
Talk to your doctor or pharmacist before taking Reagila, or during treatment if you have: - ever experienced or start to experience restlessness and inability to sit still. 
Pred začetkom jemanja zdravila Reagila ali med zdravljenjem se posvetujte z zdravnikom ali farmacevtom, zlasti če: - ste kadar koli imeli ali začenjate opažati nemir in nesposobnost sedeti pri miru.
The plasma concentration of total cariprazine decreases by 50% in ~1 week and greater than 90% decline in total cariprazine concentration occurs in ~3 weeks. 
Koncentracije skupnega kariprazina v plazmi se zmanjšajo za 50 % v ~ 1 tednu, po ~3 tednih pa je skupni upad koncentracije kariprazina več kot 90 %.
The mean terminal half-life (1 to 3 days for cariprazine and DCAR and 13 to 19 days for DDCAR) is not predictive of time to reach steady state or plasma concentration decline after treatment discontinuation. 
S povprečno končno razpolovno dobo (1 do 3 dni za kariprazin in DCAR in 13 do 19 dni za DDCAR) ni možno napovedati časa do doseženega stanja dinamičnega ravnovesja ali upada koncentracije v plazmi po prekinitvi zdravljenja.
Women of childbearing potential must use highly effective contraception while taking cariprazine and at least for 10 weeks after stopping treatment (see sections 4.5 and 4.6). 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem s kariprazinom in še vsaj 10 tednov po prenehanju zdravljenja (glejte poglavji 4.5 in 4.6).
Cariprazine has no appreciable affinity for cholinergic muscarinic receptors (IC50 > 1000 nM). 
Kariprazin nima opazne afinitete za holinergične muskarinske receptorje (IC50 > 1.000 nM).
Cariprazine should be used with caution in patients with known cardiovascular disease predisposing to blood pressure changes. 
Kariprazin je treba uporabljati previdno pri bolnikih z znanimi kardiovaskularnimi boleznimi, ki povečajo nagnjenost za spremembe krvnega tlaka.
Neonates exposed to antipsychotics (including cariprazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
Pri novorojencih, izpostavljenih antipsihotikom (vključno s kariprazinom) v tretjem trimesečju nosečnosti, obstaja tveganje za neželene učinke, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, ki se lahko po resnosti in trajanju po porodu razlikujejo.
Schizophrenia is a disease characterised by symptoms such as hearing, seeing or sensing things which are not there (hallucination), suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. 
Shizofrenija je bolezen, za katero so značilni simptomi, kot so slušne, vidne in čutne zaznave neobstoječih stvari (halucinacije), sumničavost, zmotna prepričanja, nepovezano govorjenje in vedenje ter čustvena praznost.
Differences on the Clinical Global Impression Severity (p=0.005) and Improvement (p<0.001) scales, 
Razlike na lestvicah celokupnega kliničnega vtisa glede resnosti (Clinical Global Impression Severity) (p = 0,005) in izboljšanja (p < 0,001) in stopnja odgovora PANSS-FSNS (PANSS FSNS ≥ 30 %
Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. 
Dodatni znaki lahko vključujejo mioglobinurijo (rabdomiolizo) in akutno ledvično odpoved.
Akathisia and restlessness is a frequently occurring adverse reaction of antipsychotics. 
Akatizija in nemir sta pogosta neželena učinka antipsihotikov.
Efficacy in predominantly negative symptoms of schizophrenia The efficacy of cariprazine for the treatment of predominantly negative symptoms of schizophrenia was investigated in a 26-week, multi-centre, double-blind, and active-controlled clinical trial. 
Učinkovitost pri pretežno negativnih simptomih shizofrenije Učinkovitost kariprazina pri zdravljenju pretežno negativnih simptomov shizofrenije so preučili v 26-tedenskem, multicentričnem, dvojno slepem in z učinkovino nadzorovanem kliničnem preskušanju.
Women using systemically acting hormonal contraceptives should add a second barrier method. 
Ženske, ki uporabljajo sistemsko delujoče hormonske contraceptive, morajo dodati še pregradno metodo.
Unchanged cariprazine is excreted by 1.2% of the dose in urine and 3.7% of the dose in feces. 
Nespremenjenega kariprazina se izloči 1,2 % odmerka z urinom in 3,7 % odmerka z blatom.
- if you experience a combination of fever, sweating, faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs of neuroleptic malignant syndrome). 
- če se pojavi kombinacija zvišane telesne temperature, znojenja, hitrejšega dihanja, mišične togosti in dremavosti ali zaspanosti (to so lahko znaki nevroleptičnega malignega sindroma).
Adverse drug reactions occurring in patients with schizophrenia 
Neželeni učinki zdravila, ki se pojavljajo pri bolnikih s shizofrenijo
Cariprazine is a P-gp inhibitor in vitro at its theoretical maximum intestinal concentration. 
Kariprazin je zaviralec P-gp in vitro pri teoretični največji koncentraciji v prebavilih.
Cariprazine and its metabolites were excreted in milk of rats during lactation. 
Kariprazin in njegovi presnovki so se izločali v mleko podgan med laktacijo.
In addition, pale, cold bodies and developmental delays (renal papillae not developed/underdeveloped and decreased auditory startle response in males) were observed in the absence of maternal toxicity. 
Poleg tega so opazili bleda, hladna telesa in zaostanke v razvoju (nerazvita/premalo razvita ledvična papila in zmanjšanje reakcije na slušni dražljaj pri samcih) v odsotnosti toksičnosti za mater.
During the schizophrenia clinical development program of cariprazine, few cataract cases were reported, characterized with minor lens opacities with no visual impairment (13/3192; 0.4%). 
Med kliničnim razvojnim programom kariprazina za zdravljenje shizofrenije so poročali o nekaj primerih katarakte, za katere je bila značilna manjša motnjava leče brez okvare vida (13/3192; 0,4 %).
Potential for cariprazine to affect other medicinal products 
Možnost, da bi kariprazin vplival na druga zdravila
Common (≥1/100 to 
Pogosti (≥ 1/100 do
No inflammation was observed at the end of 2-month drug-free period at an exposure 4.2 times the clinical exposure at the MRHD; however, inflammation was still present at higher doses. 
Ob koncu 2-mesečnega obdobja brez zdravila niso opazili vnetja ob izpostavljenosti, ki je bila 4,2-kratnik klinične izpostavljenosti pri MRHD; vendar je bilo pri večjih odmerkih vnetje še vedno prisotno.
In female rats, lower fertility and conception indices were observed at clinically relevant exposures based on mg/m2 body surface area. 
Pri podganjih samicah so opazili nižje indekse plodnosti in zanositve pri klinično pomembnih izpostavljenostih na podlagi mg/m2 telesne površine.
Printing ink (black: 1.5 mg, 3 mg and 6 mg capsules) 
Črnilo (črno: 1,5 mg, 3 mg in 6 mg kapsule)
The dose can be modified based on individual response and tolerability (see section 4.8). 
Odmerek se lahko prilagodi glede na odziv in prenašanje zdravila pri posamezniku (glejte poglavje 4.8).
This suggests that an interaction of cariprazine with inhibitors of P-gp, OATP1B1, OATP1B3 and BCRP is unlikely. 
To kaže, da interakcija kariprazina z zaviralci P-gp, OATP1B1, OATP1B3 in BCRP ni verjetna.
PANSS-FSNS at Baseline PANSS-FSNS at Week 26 PANSS-FSNS CfB to Week 26 
PANSS-FSNS ob izhodišču PANSS -FSNS v 26. tednu
The plasma concentration of total cariprazine will gradually decline following dose discontinuation or interruption. 
Skupne koncentracije kariprazina v plazmi po prenehanju ali prekinitvi odmerjanja upadajo postopoma.
In rabbits, cariprazine caused maternal toxicity, but no foetal toxicity at exposures 5.8 times the clinical exposure at the MRHD. 
Pri kuncih je kariprazin povzročil toksičnost za mater, vendar ni bilo toksičnosti za plod pri izpostavljenosti 5,8-kratnika klinične izpostavljenosti pri MRHD.
Following administration of 12.5 mg/day cariprazine to patients with schizophrenia, 20.8% of the dose was excreted in urine as cariprazine and its metabolites. 
Po dajanju kariprazina v odmerku 12,5 mg/dan bolnikom s shizofrenijo se 20,8 % odmerka izloči z urinom v obliki kariprazina in njegovih presnovkov.
No patients treated with cariprazine experienced QTc increases ≥ 60 msec from baseline, nor did any patient experience a QTc of > 500 msec in the study. 
Noben bolnik, zdravljen s kariprazinom, ni imel povečanja QTc ≥ 60 msek od izhodišča, in noben bolnik v študiji ni imel QTc > 500 msek.
Due to the long half-life of the active moieties of cariprazine a further increase in plasma exposure of total cariprazine can be expected during longer co-administration. 
Zaradi dolge razpolovne dobe aktivnih sestavin kariprazina se lahko pri daljšem sočasnem dajanju pričakuje nadaljnje povečanje izpostavljenosti skupnemu kariprazinu v plazmi.
QT- prolongation 
Podaljšanje intervala QT
SPECIAL STORAGE CONDITIONS Keep the blister in the outer carton in order to protect from light. 
POSEBNA NAVODILA ZA SHRANJEVANJE Pretisni omot shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Administration of a single dose of 1.5 mg cariprazine with a high-fat meal (900 to 1,000 calories) did not significantly affect the Cmax or AUC of cariprazine (AUC0-∞ increased by 12%, Cmax decreased by < 5% under fed condition versus fasting). 
Enkratno dajanje odmerka 1,5 mg kariprazina z obrokom, bogatim z maščobami (900 do 1.000 kalorij) ni pomembno vplivalo na Cmax ali AUC kariprazina (AUC0-∞ se je povečal za 12 %, Cmax se je zmanjšal za < 5 % v pogojih s hrano v primerjavi s stanjem na tešče).
Following multiple-dose administration, peak plasma concentrations for cariprazine and the major active metabolites generally occur at approximately 3-8 hours post dose. 
Po večkratnem dajanju odmerkov se največje koncentracije kariprazina in glavnih aktivnih presnovkov v plazmi običajno pojavijo približno 3 do 8 ur po odmerku.
The capsules are packed in transparent hard PVC/PE/PVDC blister heat-sealed with hard aluminium foil backing. 
Kapsule so pakirane v prozorne trde pretisne omote iz PVC/PE/PVDC, toplotno zavarjene s trdo aluminijasto folijo na hrbtni strani.
If you are using hormonal contraceptives a so-called barrier method should also be used (see section “Pregnancy and breast-feeding” below). 
Če uporabljate hormonske kontraceptive, morate uporabljati tudi tako imenovano pregradno metodo (glejte spodnje poglavje „Nosečnost in dojenje“).
An additional metabolite, desdichlorophenyl piperazine cariprazine (DDCPPCAR) acid, is produced by dealkylation and subsequent oxidation of cariprazine. 
Dodatni presnovek, dezdiklorofenil piperazin kariprazinska kislina (DDCPPCAR), nastane z dealkilacijo in sledečo oksidacijo kariprazina.
Cariprazine caused bilateral cataract and secondary retinal changes (retinal detachment and cystic degeneration) in the dog. 
Kariprazin je pri psih povzročil obojestransko katarakto in sekundarne mrežnične spremembe (odstop mrežnice in cistično degeneracijo).
Population pharmacokinetic modelling was performed using data from patients enrolled in the schizophrenia cariprazine clinical program with differing levels of renal function, including normal renal function (creatinine clearance (CrCl) ≥ 90 mL/min), as well as mild (CrCl 60 to 89 mL/min) and moderate (CrCl 30 to 59 mL/min) renal impairment. 
Modeliranje populacijske farmakokinetike so izvedli s podatki bolnikov, vključenih v klinični program kariprazina za zdravljenje shizofrenije, z različnimi ravnmi okvare ledvic, vključno z normalnim delovanjem ledvic (očistek kreatinina (CrCl, creatinine clearance) ≥ 90 ml/min), in blago (CrCl 60 do 89 ml/min) ter zmerno (CrCl 30 do 59 ml/min) okvaro ledvic.
(Rare side effect) - combination of fever, sweating, muscle stiffness, and drowsiness or sleepiness. 
(Redek neželeni učinek) - kombinacija zvišane telesne temperature, znojenja, mišične togosti in dremavost ali zaspanost.
The most frequently reported ADRs with cariprazine in the dose range (1.5-6 mg) were akathisia (19%) and parkinsonism (17.5%). 
Najpogosteje poročana neželena učinka s kariprazinom v celotnem razponu odmerkov (1,5-6 mg) sta bila akatizija (19 %) in parkinsonizem (17,5 %).
Total cariprazine (sum of cariprazine + DCAR and DDCAR) exposure approaches 50% of steady state exposure in ~1 week of daily dosing while 90% of steady state is achieved in 3 weeks. 
Skupna izpostavljenost kariprazinu (vsota kariprazin + DCAR in DDCAR) se približa 50 % vrednosti izpostavljenosti v stanju dinamičnega ravnovesja po ~1 tednu dnevnega odmerjanja, medtem ko je 90 % stanja dinamičnega ravnovesja doseženo v 3 tednih.
Cariprazine (dose range 3-6 mg, target dose 4.5 mg) was investigated compared to risperidone (dose range 3-6 mg, target dose 4 mg) in patients with persistent, predominant negative symptoms of schizophrenia (n=461). 
Kariprazin (razpon odmerka od 3 do 6 mg, ciljni odmerek 4,5 mg) so preučili v primerjavi z risperidonom (razpon odmerka od 3 do 6 mg, ciljni odmerek 4 mg) pri bolnikih z vztrajnimi, pretežno negativnimi simptomi shizofrenije (n = 461).
It is currently unknown whether cariprazine may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives should add a second barrier method. 
Trenutno ni znano, ali lahko kariprazin zmanjša učinkovitost sistemsko delujočih hormonskih kontraceptivov, zato morajo ženske, ki uporabljajo sistemsko delujoče hormonske kontraceptive, uporabljati še drugo, pregradno metodo.
You may experience dizziness from low blood pressure, or have abnormal heartbeats, you may feel sleepy, tired, or have abnormal body movements and find it difficult to stand or walk. 
Morda boste omotični zaradi nizkega krvnega tlaka, imeli nenormalni srčni utrip, boste zaspani, utrujeni ali pa boste imeli nenormalne telesne gibe in težave pri stanju ali hoji.
Taking Reagila together with some medicines may require a dose adjustment of Reagila or the other medicine. 
Če jemljete zdravilo Reagila skupaj z nekaterimi drugimi zdravili, bo morda treba prilagoditi odmerek zdravila Reagila ali drugega zdravila.
It is currently unknown if cariprazine may reduce the effectiveness of systemically acting hormonal contraceptives and therefore women using systemically acting hormonal contraceptives should add a barrier method (see section 4.5). 
Trenutno ni znano, ali lahko kariprazin zmanjša učinkovitost sistemsko delujočih hormonskih kontraceptivov, zato morajo ženske, ki uporabljajo sistemsko delujoče hormonske contraceptive, uporabljati še drugo, pregradno metodo (glejte poglavje 4.5).
Administration of cariprazine to rats during the period of organogenesis caused malformations, lower pup survival, and developmental delays at drug exposures less than the human exposure at the MRHD of 6 mg/day. 
Dajanje kariprazina podganam v obdobju organogeneze je povzročilo malformacije, manjše preživetje mladičev in zaostanek v razvoju pri izpostavljenosti zdravilu, ki je bila nižja od izpostavljenosti pri ljudeh z MRHD 6 mg/dan.
Akathisia is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. 
Akatizija je motnja gibanja, za katero sta značilna občutek notranjega nemira in nujna potreba po stalnem gibanju pa tudi gibi, kot so zibanje med stanjem ali sedenjem, dviganje stopal kot pri korakanju na mestu in prekrižanje ter odkrižanje nog med sedenjem.
The metabolism of cariprazine involves demethylation (DCAR and DDCAR), hydroxylation (hydroxy cariprazine, HCAR) and a combination of demethylation and hydroxylation (hydroxy desmethyl cariprazine, HDCAR and hydroxy didesmethyl cariprazine, HDDCAR). 
Presnova kariprazina vključuje demetilacijo (DCAR in DDCAR), hidroksilacijo (hidroksi-kariprazin, HCAR) in kombinacijo demetilacije in hidroksilacije (hidroksi-desmetil kariprazin, HDCAR in hidroksi-didesmetil kariprazin, HDDCAR).
In the open-label phase of the study during 20 weeks cariprazine treatment 9.0% of patients developed potentially clinically significant (PCS) weight gain (defined as increase ≥ 7%) while during the double-blind phase, 9.8 % of the patients who continued with cariprazine treatment had PCS weight gain versus 7.1% of the patients who were randomized to placebo after the 20 week open-label cariprazine treatment. 
V odprti fazi študije so med 20 tedni zdravljenja s kariprazinom pri 9,0 % bolnikov poročali o potencialno klinično pomembnem zvečanju telesne mase (opredeljenem kot zvečanje ≥ 7 %), medtem ko so po 20 tednih odprtega zdravljenja s kariprazinom med dvojno slepo fazo zabeležili potencialno klinično pomembno zvečanje telesne mase pri 9,8 % bolnikov, ki so nadaljevali zdravljenje s kariprazinom, v primerjavi s 7,1 % bolnikov, randomiziranih na placebo.
Cariprazine and its major active metabolites did not induce CYP1A2, CYP2B6 and CYP3A4 enzymes and were not inhibitors of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP219, CYP2D6, CYP2E1 and CYP3A4 in vitro. 
Kariprazin in njegova glavna aktivna presnovka in vitro niso inducirali encimov CYP1A2, CYP2B6 ter CYP3A4 in niso bili zaviralci CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP219, CYP2D6, CYP2E1 in CYP3A4.
Safety and efficacy of cariprazine have not been evaluated in patients with severe renal impairment (CrCl < 30 mL/min). 
Varnost in učinkovitost kariprazina nista bili ocenjeni pri bolnikih s hudo okvaro ledvic (CrCl < 30 ml/min).
The recommended starting dose is 1.5 mg once a day by mouth. 
Priporočeni začetni odmerek je 1,5 mg enkrat na dan peroralno.
Change From Baseline to Week 6 in the PANSS Total Score in Studies of Acute Exacerbations of Schizophrenia-ITT Population 
Sprememba od izhodišča do 6. tedna v skupni vrednosti PANSS v študijah akutne eksacerbacije shizofrenije pri populaciji ITT Izhodišče povprečje
Absolute bioavailability of cariprazine is unknown. 
Absolutna biološka uporabnost kariprazina ni znana.
CYP2D6 mediated pathway plays a minor role in the metabolism of cariprazine, the major pathway is via CYP3A4 (see section 5.2). 
Pot, pri kateri posreduje CYP2D6, ima manjšo vlogo pri presnovi kariprazina, glavna pot poteka prek CYP3A4 (glejte poglavje 5.2).